摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[(3R)-3-hydroxy-2,2-dimethyl-4-[[3-(2-methylsulfanylethylamino)-3-oxopropyl]amino]-4-oxobutyl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

中文名称
——
中文别名
——
英文名称
[(3R)-3-hydroxy-2,2-dimethyl-4-[[3-(2-methylsulfanylethylamino)-3-oxopropyl]amino]-4-oxobutyl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
英文别名
——
[(3R)-3-hydroxy-2,2-dimethyl-4-[[3-(2-methylsulfanylethylamino)-3-oxopropyl]amino]-4-oxobutyl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate化学式
CAS
——
化学式
C32H52N2O5S
mdl
——
分子量
576.8
InChiKey
BOTHZNLLEOMBOM-ZZEJBEKTSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.7
  • 重原子数:
    40
  • 可旋转键数:
    24
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.59
  • 拓扑面积:
    130
  • 氢给体数:
    3
  • 氢受体数:
    6

文献信息

  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION AND LIPID DISORDERS
    申请人:Kandula Mahesh
    公开号:US20150057347A1
    公开(公告)日:2015-02-26
    The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammation and lipid disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of hypertriglyceridemia, steatohepatitis, cystinosis and inflammatory diseases.
    该发明涉及公式I和公式II的化合物或其药用可接受的盐,以及其多晶型、溶剂合物、对映体、立体异构体和合物。包括有效量的公式I或公式II化合物的药物组合物;以及用于治疗或预防炎症和脂质紊乱的方法可以制成口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射剂。这种组合物可用于治疗高三酸甘油酯血症、脂肪肝、半胱酸症和炎症性疾病。
  • [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DU SYNDROME DU CÔLON IRRITABLE
    申请人:CELLIX BIO PRIVATE LTD
    公开号:WO2018029545A1
    公开(公告)日:2018-02-15
    The disclosures herein provide compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, formula XII, formula XIII, formula XIV and formula XV or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, suppository, transdermal, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of irritable bowel syndrome (IBS), inflammatory bowel diseases or its associated complications.
    本公开提供化合物的公式I、公式II、公式III、公式IV、公式V、公式VI、公式VII、公式VIII、公式IX、公式X、公式XI、公式XII、公式XIII、公式XIV和公式XV,或其药用可接受盐,以及其多型、对映体、立体异构体、溶剂合物和合物。这些盐可以制成药物组合物。药物组合物可以制成口服、栓剂、经皮、颊部、直肠、局部、经皮、经粘膜、静脉、全身、糖浆或注射用药物。这些组合物可用于治疗肠易激综合征(IBS)、炎症性肠病或其相关并发症。
  • [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND INFLAMMATION<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE MALADIES NEUROLOGIQUES ET D'UNE INFLAMMATION
    申请人:KANDULA MAHESH
    公开号:WO2014115098A1
    公开(公告)日:2014-07-31
    The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing neurological diseases and inflammation, a neurological disease, allergy, respiratory diseases or inflammatory disorder may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of muscle disorders, neurological diseases and inflammation, spasticity, neuropathic pain, fibromyalgia, Parkinson's disease, allergy, asthma, chronic obstructive pulmonary disease, allergic rhinitis, headache, chronic pain, sub-chronic pain and local pain or its associated complications.
    该发明涉及具有化学式I或其药用可接受的盐的化合物,以及其多型、溶剂合物、对映体、立体异构体和合物。包括化学式I化合物的有效量的药物组合物;以及用于治疗或预防神经系统疾病和炎症、神经系统疾病、过敏、呼吸系统疾病或炎症性疾病的方法,可以制备用于口服、颊内、直肠、局部、经皮、经粘膜、静脉内、肠道、糖浆或注射的药物组合物。这些组合物可以用于治疗肌肉障碍、神经系统疾病和炎症、痉挛、神经病性疼痛、纤维肌痛、帕森病、过敏、哮喘、慢性阻塞性肺病、过敏性鼻炎、头痛、慢性疼痛、亚慢性疼痛和局部疼痛或其相关并发症的治疗。
  • US9670153B2
    申请人:——
    公开号:US9670153B2
    公开(公告)日:2017-06-06
  • [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE MALADIES NEUROLOGIQUES ET NEURODÉGÉNÉRATIVES
    申请人:KANDULA MAHESH
    公开号:WO2014060925A2
    公开(公告)日:2014-04-24
    The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of seizures, Huntington's disease, spasms, mental diseases, mental disorders, schizophrenia, depression, bipolar disorder, Alzheimer's disease, anxiety, ADHD, dementia, mood disorders, PTSD, sleeplessness, epilepsy, migraine, psychosis, OCD, autism, anxiety disorders, dementia, mania, cognitive disorders.
查看更多